Clinical trial NCT05366621: Post-fracture Medication and Mortality
Official title: The Association Between Anti-osteoporosis Medications and Lowered All Cause Mortality After Osteoporotic Fractures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoporosis
Osteoporosis Fracture
Drug Therapy
Mortality
Adherence, Medication
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2022-05-09
Enrollment: 216155
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The final study participants included those who satisfied the inclusion criteria for both osteoporosis and hip fracture cohorts, and they were followed until 2018.

Brief summary: Osteoporotic fracture is a common public-health problem in the whole world. Although postfracture usage of anti-osteoporosis medications, may reduce mortality, recent results have been inconsistent. The investigators aim to examine associations between osteoporosis medication and mortality in older adults and any type of fracture patients. The investigators also aim to discuss the pleiotropic effects of different types of anti-osteoporosis medications.

Detailed description: Osteoporotic fracture has become a serious health and economic burden as life expectancy increases. In a WHO report, the burden of osteoporotic fractures in 2002 was 2.8 million disability-adjusted life years, which is more than that for hypertension and slightly less than that for diabetes mellitus or chronic obstructive pulmonary diseases. Many patients who have had a diagnosed fracture have never been diagnosed with osteoporosis, therefore, closing the gap in osteoporosis treatment is important. This situation is primarily due to the fact that osteoporosis symptoms are often not recognized until a fracture occurs. Osteoporotic fractures, especially those of the hip and vertebral, are associated with an increased risk of death. Early detection of high risk for osteoporotic fractures is important; however, post-fracture management, especially interventions intended to lower mortality, is an emerging public health issue in rapidly aging societies. The burden of osteoporotic fracture is higher than that of hypertension, however, osteoporosis is always given less attention than other chronic diseases by health professionals and the general population.

Eligibility criteria: Inclusion Criteria:

* Newly diagnosed osteoporosis and hip fracture are defined as a claim record from the NHIRD between 2009 and 2017.

Exclusion Criteria:

* Patients with a diagnosis of osteoporosis or osteoporotic fractures in 2008 or before were excluded.

Primary outcomes:
measure: Number of deaths with and without anti-osteoporotic therapy after hip fracture surgery
timeFrame: 12 years
measure: Number of deaths with or without anti-osteoporosis therapy after hip or vertebral fracture surgery among older adults
timeFrame: 12 years
measure: Number of deaths with and without bisphosphonates after hip or spine fracture surgery
timeFrame: 12 years
measure: Number of deaths with different types of anti-osteoporosis treatments after post-fracture
timeFrame: 12 years
measure: Number of deaths in five leading causes of death with and without anti-osteoporosis treatment after post-fracture
timeFrame: 12 years
Secondary outcomes:
Other outcomes:
Locations:
city: Tainan
country: Taiwan
facility: Department of Family Medicine, National Cheng Kung Univ Hosp
Study officials:
affiliation: National Cheng Kung University
name: Chih-Hsing Wu, MD
role: STUDY_DIRECTOR
References: